---
document_datetime: 2024-07-30 10:09:39
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pemetrexed-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pemetrexed-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6078487
conversion_datetime: 2025-12-18 21:36:55.04125
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                             | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                       |
|----------------------|---------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0009               | Renewal of the marketing authorisation. Medicinal | 15/12/2022                                  | 15/02/2023                                  | SmPC                             | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pemetrexed Krka in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Pemetrexed Krka Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0008     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH         | 24/08/2022   | 15/02/2023   | SmPC and PL                      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|
| N/0007      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                     | 14/09/2021   | 18/11/2021   | PL authorised                    |
| IAIN/0006/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer    | 16/03/2021   | n/a no       | longer                           |
| IB/0005     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product | 04/11/2020   | 18/11/2021   | SmPC, Annex II, Labelling and PL |
| IB/0004     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) Medicinal                                                                                                                  | 07/11/2019   | 04/05/2020   | SmPC                             |
| IB/0003     | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure                                                                                                                                                                     | 17/05/2019   | 04/05/2020   | SmPC and PL                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->